Olink Bioscience introduces its new Plasma Biomarker Discovery Service

Olink Bioscience now offers a new research service, Plasma Biomarker Discovery Service. Using the multiplexed PLA® immunoassay platform, up to 74 potential cancer biomarkers are analyzed with high sensitivity in precious biobanked plasma samples, in no more than 2 µl of sample. The Plasma Biomarker Discovery Service will help scientists in industry and academia to identify novel biomarkers and contribute to the understanding of human cancer and improved diagnosis.

"PLA has an industry leading sensitivity of multiplexed immunoassays while only consuming minute amounts of sample. Researchers can now access precious and limited biobanked serological materials and with our service find new protein biomarker signatures." says Dr Simon Fredriksson, Chief Scientific Officer at Olink Bioscience.

The PLA immunoassay technology employs two primary antibodies linked to DNA strands, which upon simultaneous and proximal binding to the target protein, will be ligated. Once ligated, they form a PCR amplicon typically detected with real-time quantitative PCR. The assay is performed as a convenient homogeneous assay without any washing steps and is characterized by low sample consumption, high sensitivity, and multiplexing capability as recently published by Lundberg et al 2011 Jan 17, Mol Cell Proteomics PMID: 21242282.

About Olink Bioscience

Olink Bioscience develops cutting-edge technologies for biomolecular analysis for use in research and diagnostics. These novel tools for protein detection and nucleic acid analyses enable researchers to see further into biology revealing new insights into basic science, drug development, and diagnostics.  The products, which are based on a strong intellectual property portfolio, are sold by Olink Bioscience and a global network of distributors. The company’s proprietary Duolink® product line enables researchers in academia and the pharmaceutical industry to visualize and accurately quantify individual proteins, their interactions and modifications, in unmodified cells and tissues. Such information is crucial to help elucidate disease mechanisms, leading to the development of novel diagnostics, therapeutics, and new drug targets. Olink’s molecular technologies are also commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Halo Genomics and Qlinea. Olink Bioscience was founded in 2004 and is headquartered in Uppsala, Sweden.

For information please contact:

Peter Karlberg                                                             
Director Sales and Marketing                                   
Olink Bioscience                                                         
Phone: +46 (0)18 444 39 70                                        
email: peter.karlberg@olink.com

Duolink is intended for research use only. Duolink is not for use in human diagnostic or therapeutic procedures. The following trademarks are owned by Olink AB: Olink®, Olink Bioscience, Duolink®, and PLA®.